Kingsoft Cloud Holdings Limited vs Royalty Pharma plc Class A Ordinary Shares — how do they compare? Kingsoft Cloud Holdings Limited trades at $9.26 (market cap $2.71B), while Royalty Pharma plc Class A Ordinary Shares trades at $56.93 (market cap $25.27B). The key difference: Royalty Pharma plc Class A Ordinary Shares is far larger — about 9.3× Kingsoft Cloud Holdings Limited's market cap, and Royalty Pharma plc Class A Ordinary Shares pays a 1.66% dividend while Kingsoft Cloud Holdings Limited pays none. Which is the better fit depends on your goals — on Pluang, investors hold Kingsoft Cloud Holdings Limited for 12 Days and Royalty Pharma plc Class A Ordinary Shares for 1 Days on average.
| KC | RPRX | |
|---|---|---|
Market Cap | $2.71B | $25.27B |
Volume | 1,993,765 | 3,671,183 |
Sector | Technology | Health |
52-Week High | $18.21 | $63.96 |
52-Week Low | $8.58 | $35.44 |
Typical Hold Time | 12 Days | 1 Days |
Enterprise Value | $3.03B | $32.50B |
Dividend Yield | — | 1.66% |
Signals from Pluang's Aura AI — not financial advice
Kingsoft Cloud (KC) trades at $8.74, down 5.31% today, with a bearish technical outlook despite recent earnings beats. The company shows strong revenue growth with Q2 2026 revenue up 30.8% year-over-year and improving gross margins, though it remains unprofitable with a -5.46% net income margin. Analyst sentiment is positive with 70% buy ratings and a consensus price target suggesting 60.25% upside potential.
The stock presents a growth opportunity driven by AI cloud services expansion and strategic partnerships, particularly with Xiaomi, but faces execution risks amid ongoing losses and competitive pressures in China's cloud market. Investors should weigh the strong growth trajectory against persistent profitability challenges and market volatility.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Kingsoft Cloud is a leading independent cloud service provider in China. It offers a comprehensive suite of cloud products and solutions tailored for industries like gaming, video streaming, and financial services.
Read more on KC →Royalty Pharma acquires interests in royalties from biopharmaceutical products. Its model gives it exposure to medicines developed and sold by other life sciences companies.
Read more on RPRX →